In today’s ACT Brief, we look at how FDA policy is accelerating the use of de-identified real-world evidence in clinical ...

Explore how large-scale, de-identified real-world datasets enable more representative trial design, improve site selection, and support patient identification beyond the limits of traditional clinical ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging ...

This latest government action impacting the research space would allocate $116.8 billion in 2026 funding to the HHS—an increase of $210 million from 2025. Within the HHS, the National Institutes of ...

Traditional clinical trial data are pseudonymized data, and these data may not contain information on a patient that directly identifies them, like a name, address, or phone number. However, ...

In today’s ACT Brief, we examine why life sciences companies are maintaining DEI commitments amid political pressure, what’s ...

Meeting sites where they are—within their systems, workflows, and technology—is something we’re deeply interested in ...

In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management ...

The clinical trials landscape will continue evolving toward greater decentralization, enhance patient-centricity, and increased global diversification. Industry projections suggest that by 2025, ...

When we think about where AI can help, it’s about reducing administrative burden. Tools like Smart Draft help streamline ...

In today’s ACT Brief, we look at efforts to address sex-based evidence gaps in Parkinson’s disease research, why ...